Navigation Links
Jefferson scientists identify gene mutation potentially involved in breast cancer initiation

Researchers at Jefferson Medical College and the Kimmel Cancer Center at Thomas Jefferson University in Philadelphia and at the Albert Einstein College of Medicine in New York have found evidence suggesting that a mutation in a gene that normally helps block the formation of breast tumors could play a role in the initiation of a major form of breast cancer.

The team, led by cell biologist Michael P. Lisanti, M.D., Ph.D., professor of cancer biology at Jefferson Medical College and Richard Pestell, M.D., Ph.D., director of Jefferson's Kimmel Cancer Center, found that a known mutation in the Caveolin-1 gene is present in approximately 19 percent of all breast cancers that are fed by estrogen ?so called "estrogen receptor-positive" cells. The group also discovered six new Caveolin-1 mutations associated with estrogen-driven breast cancers. As many as nearly 35 percent of such breast cancers may carry Caveolin-1 mutations, Dr. Lisanti says. Caveolin proteins, which play important roles in cell communication, are also involved in a number of diseases and conditions, such as cancer, atherosclerosis, diabetes, Alzheimer's disease and muscular dystrophy.

The researchers, reporting in June 2006 in the American Journal of Pathology, say their results open up the possibility that Caveolin-1 mutations may be involved in the development of estrogen-positive human breast cancer, which accounts for some 70 percent of all breast cancers. "This is the first demonstration that a specific Caveolin-1 mutation is exclusively connected to being estrogen-receptor positive," says Dr. Lisanti, noting that in tests of breast tumor samples, none of those that were estrogen-receptor negative showed caveolin mutations.

"One-third of estrogen receptor-positive patients actually had caveolin mutations, making it one of the most common mutations in that population," he says. "Usually about 70 percent of all human breast cancers are estrogen receptor-positive and 30 perce nt are negative. That's one-third of the major form of human breast cancer."

Dr. Lisanti explains that he and his colleagues had wanted to test the hypothesis that the loss of a functioning Caveolin-1 gene could increase the activity, or "upregulate" the expression of estrogen receptors. Only 5 to 10 percent of the cells in the normal human breast express estrogen receptors, yet the receptor activity for some reason rises dramatically in premalignant lesions and cancer.

Dr. Lisanti's team developed mice lacking the Caveolin-1 gene and found a dramatic increase in both number and activity of estrogen-positive receptors in mouse breast tissue, specifically in breast epithelial cells, in turn, promoting cell growth. Caveolin-1, Dr. Lisanti suggests, could act as a kind of "switch" that regulates receptor activity and cell proliferation.

"It is the first time that we can say that the loss of function of caveolin gene expression plays a role in the specific upregulation of estrogen receptor," he says. "It helps explain the nature of this transition from nonmalignant to malignant tissue."

Dr. Lisanti explains that estrogen receptors are thought to help turn on certain genes such as cyclin D1, which in turn promote cancer development. "We've elicited a new pathway for mammary tumorigenesis," he says. "Before, we could say that estrogen receptors turned on cyclin D1, which was enough to cause mammary tumorigenesis. Now we've added another link: inactivation of caveolin as the first initiation step."

The team found that cyclin D1 activity in human breast cancer samples was increased, specifically after estrogen treatment. "In essence, we have created a preclinical model in which to study the role of estrogen and caveolin deficiency in breast cancer development," he says. "It's a new signaling pathway for understanding the pathogenesis of human breast cancer with caveolin gene inactivation as the initiating step. It all fits togethe r."

The group subsequently showed in laboratory studies that in mouse mammary cells lacking caveolin and certain growth-stimulating factors, estrogen receptors were again increased, leading them to conclude that two factors may be required for estrogen receptor upregulation: Caveolin gene inactivation and growth factor depletion.

The findings may have clinical implications. According to Dr. Lisanti, those breast cancer patients who are estrogen receptor-positive and who have caveolin mutations are much more likely to have a cancer recur than are such individuals who don't carry caveolin gene mutations. "It's a risk factor," he notes.


'"/>

Source:Thomas Jefferson University


Related biology news :

1. Jefferson Virologists Coax HIV Out of Hiding
2. Jefferson researchers find nanoparticle shows promise in reducing radiation side effects
3. Jefferson biologist coaxing human embryonic stem cells to make dopamine with simpler, faster method
4. Jefferson scientists identify gene defect leading to abnormal skin development and cancer
5. Jefferson researchers building a better rabies vaccine
6. Immune cell communication key to hunting viruses, Jefferson immunologists show
7. Jefferson researchers uncover new way nature turns genes on and off
8. Jefferson scientists find aging gene also protects against prostate cancer development
9. Jefferson scientists find high glucose before surgery raises risk of dangerous complications
10. Jefferson researchers discovery may change thinking on how viruses invade the brain
11. Elderly spinal cord injuries increase five-fold in 30 years, Jefferson neurosurgeons find
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/17/2017)... April 17, 2017 NXT-ID, Inc. (NASDAQ: ... the filing of its 2016 Annual Report on Form 10-K on ... ... is available in the Investor Relations section of the Company,s website ... SEC,s website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... BROOKLYN, N.Y. , April 11, 2017 /PRNewswire-USNewswire/ ... identical fingerprints, but researchers at the New York ... University College of Engineering have found that partial ... fingerprint-based security systems used in mobile phones and ... previously thought. The vulnerability lies in ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... for two-dimensional representations of a complex biological network, a depiction of a system ... big mess,” said Dmitry Korkin, PhD, associate professor of computer science at Worcester ...
(Date:10/12/2017)... ... 12, 2017 , ... BioMedGPS announces expanded coverage of SmartTRAK ... module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and Sealants ... sealants and biologic sealants used in surgical applications. BioMedGPS estimates the market will ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
Breaking Biology Technology: